Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer
1998

Carboplatin and Etoposide for Elderly Patients with Small-Cell Lung Cancer

Sample size: 38 publication Evidence: moderate

Author Information

Author(s): K Matsui, N Masuda, M Fukuoka, T Yana, T Hirashima, T Komiya, M Kobayashi, M Kawahara, S Atagi, M Ogawara, S Negoro, S Kudoh, K Furuse

Primary Institution: Osaka Prefectural Habikino Hospital

Hypothesis

Can the Egorin's carboplatin dosing formula combined with oral etoposide effectively treat elderly patients with small-cell lung cancer?

Conclusion

The combination of carboplatin and oral etoposide is effective and tolerable for elderly patients with small-cell lung cancer.

Supporting Evidence

  • The overall response rate was 81%.
  • Median survival times were 15.1 months for limited-disease patients and 8.6 months for extensive-disease patients.
  • Myelosuppression was the principal side effect observed.
  • Two treatment-related deaths were noted in patients with extensive disease.

Takeaway

Doctors tested a new way to give chemotherapy to older people with lung cancer, and it worked well for many of them.

Methodology

A phase II trial evaluated the efficacy and toxicity of carboplatin and oral etoposide in 38 elderly patients with small-cell lung cancer.

Limitations

The study had a small sample size and included only patients over 70 years old.

Participant Demographics

Median age was 78 years, with 30 males and 8 females.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication